Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Viking Therapeutics Inc

VKTX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$33.19

▲ +0.76%

Market Cap $3.87B · Vol 358.96K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.87B

Mid Cap

Div Yield

N/A

EPS Growth

-49.47%

YoY

RSI (14)

40.05

Momentum

Beta

0.67

vs Market

52W High

$43.11

23.01% below

52W Low

$22.96

44.56% above

Volume

358.96K

Avg 610.68K

P/B

6.32

Price-to-book

ROE

-47.34%

Return on equity

Free Float

96.91%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Viking Therapeutics Inc (VKTX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does VKTX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.12%

-12.59%

+4.67%

+14.45%

YTD

-5.66%

-17.52%

+124.11%

+461.59%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-359,639,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-47.34%
ROA · ROIC	-44.29% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	6.32
P/FCF	N/A
EPS Growth	-49.47%
Outstanding Shares	116.65M

Technical Indicators

50-Day SMA	$34.55
200-Day SMA	$33.78
RSI (14)	40.05
Beta	0.67
52-Week High	$43.11
52-Week Low	$22.96

Volume Today	358.96K
Avg Daily Volume (30D)	610.68K
Relative Volume	0.59x
Volatility (10D)	28.70
Volatility (30D)	49.08
Free Float	96.91%

Analyst Consensus

BUY

Current Price $33.19

Mean Target $94.76

52W Low$22.96 52W High$43.11

Current

Target

$22.96 $43.11

Current Analyst target

+185.52% upside potential · 20 analysts

Identifiers

ExchangeNasdaq

FIGIBBG006LGV887

ISINUS92686J1060

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateOct 20, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.